Hybio Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Yu Pinxiang

İcra Kurulu Başkanı

CN¥1.8m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	5.5yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	3.1yrs
Yönetim Kurulu ortalama görev süresi	4.7yrs

Son yönetim güncellemeleri

Recent updates

Investor Optimism Abounds Hybio Pharmaceutical Co., Ltd. (SZSE:300199) But Growth Is Lacking

Sep 30

Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt

Jul 20

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues

Jun 03

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up

Feb 29

Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?

Feb 26

CEO

Yu Pinxiang (51 yo)

5.5yrs

Görev süresi

CN¥1,842,600

Tazminat

Ms. Pinxiang Yu serves as Director of Hybio Pharmaceutical Co., Ltd. since May 31, 2019 and serves as its Executive President. She served as a Vice President of Production Department at Hybio Pharmaceutica...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yu Pinxiang	Executive President & Director	no data	CN¥1.84m	0.060% CN¥ 6.1m
Honghong Tu	VP, CFO & Accounting Supervisor	3.3yrs	CN¥649.80k	Veri yok
Di Yang	VP, Secretary & Director	2.8yrs	CN¥781.00k	Veri yok
Zhaohui Zeng	Vice President	3.3yrs	CN¥1.19m	Veri yok
Min Zhang	Vice President	2.9yrs	CN¥616.50k	Veri yok
Heng Quan	Vice President of Human Resource & Administration Department	no data	CN¥840.50k	Veri yok
Yu Liu	Vice President of Marketing	no data	CN¥398.30k	Veri yok

3.1yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: 300199 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yu Pinxiang	Executive President & Director	5.5yrs	CN¥1.84m	0.060% CN¥ 6.1m
Di Yang	VP, Secretary & Director	4.6yrs	CN¥781.00k	Veri yok
Lian Zhong	Independent Director	3.3yrs	CN¥60.00k	Veri yok
Shaobin Zeng	Non-Independent Director	4.8yrs	CN¥65.70k	2.46% CN¥ 251.5m
Lu Yang	Member of Non-Employee Supervisory Board	2.9yrs	Veri yok	Veri yok
Qingyang Li	Chairman of Supervisory Board	5.5yrs	Veri yok	Veri yok
Yangming Tang	VP & Director	3.8yrs	CN¥976.90k	Veri yok
Wenyan Hu	Independent Director	2.9yrs	CN¥120.00k	Veri yok
Shaoqiang Zeng	Vice Chairman	15yrs	CN¥60.10k	8.15% CN¥ 833.6m
Shaogui Zeng	Chairman	15yrs	CN¥1.12m	12.41% CN¥ 1.3b
Lin Liang	Supervisor	no data	Veri yok	Veri yok

4.7yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300199 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).

Hybio Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.045 loss per share (vs CN¥0.15 loss in 3Q 2023)

Hybio Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor Optimism Abounds Hybio Pharmaceutical Co., Ltd. (SZSE:300199) But Growth Is Lacking

Second quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.068 loss in 2Q 2023)

Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: CN¥0.02 loss per share (vs CN¥0.02 profit in 1Q 2023)

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Hybio Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up

Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?

Hybio Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: CN¥0.15 loss per share (vs CN¥0.05 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.068 loss per share (vs CN¥0.049 loss in 2Q 2022)

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.06 loss in 1Q 2022)

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.096 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.049 loss per share (vs CN¥0.058 loss in 2Q 2021)

Hybio Pharmaceutical Co., Ltd. (SZSE:300199) agreed to acquire 10.81% stake in Hybio Biotechnology (Dali) Co., Ltd. from Dazhong Transportation (Group) Co., Ltd. (SHSE:600611) for CNY 20 million.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

High number of new and inexperienced directors

Third quarter 2021 earnings released: CN¥0.096 loss per share (vs CN¥0.009 profit in 3Q 2020)

Less than half of directors are independent

First quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.025 in 1Q 2020)

Hybio Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥5.60

New 90-day low: CN¥6.66

New 90-day low: CN¥7.17

New 90-day low: CN¥7.43

Third quarter earnings released

Hybio Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

New 90-day high - CN¥7.95

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 14, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş